These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28386710)

  • 1. The effect of using a robust optimality criterion in model based adaptive optimization.
    Strömberg EA; Hooker AC
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):317-324. PubMed ID: 28386710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.
    Pierrillas PB; Fouliard S; Chenel M; Hooker AC; Friberg LE; Karlsson MO
    AAPS J; 2018 Mar; 20(2):39. PubMed ID: 29516207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.
    Loingeville F; Nguyen TT; Riviere MK; Mentré F
    J Biopharm Stat; 2020; 30(1):31-45. PubMed ID: 31032703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust population pharmacokinetic experiment design.
    Dodds MG; Hooker AC; Vicini P
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):33-64. PubMed ID: 16205840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
    Tod M; Rocchisani JM
    J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robustness of optimal design of fMRI experiments with application of a genetic algorithm.
    Maus B; van Breukelen GJ; Goebel R; Berger MP
    Neuroimage; 2010 Feb; 49(3):2433-43. PubMed ID: 19833212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria.
    Tod M; Rocchisani JM
    Comput Methods Programs Biomed; 1996 Jun; 50(1):13-22. PubMed ID: 8835836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A generalisation of T-optimality for discriminating between competing models with an application to pharmacokinetic studies.
    Vajjah P; Duffull SB
    Pharm Stat; 2012; 11(6):503-10. PubMed ID: 23059829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models.
    Papathanasiou T; Strathe A; Overgaard RV; Lund TM; Hooker AC
    AAPS J; 2019 Jul; 21(5):95. PubMed ID: 31359219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of robust criteria for D-optimal designs.
    Foo LK; McGree J; Eccleston J; Duffull S
    J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An estimation method of the clearance for a one-compartment model of a single bolus intravenous injection by a single sampling.
    Funatogawa T; Funatogawa I
    J Biopharm Stat; 2012; 22(1):43-53. PubMed ID: 22204526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of Fisher information matrix approximation methods in population optimal design calculations.
    Strömberg EA; Nyberg J; Hooker AC
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):609-619. PubMed ID: 27804003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal flexible sample size design with robust power.
    Zhang L; Cui L; Yang B
    Stat Med; 2016 Aug; 35(19):3385-96. PubMed ID: 26999385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive-optimal design in PET occupancy studies.
    Zamuner S; Di Iorio VL; Nyberg J; Gunn RN; Cunningham VJ; Gomeni R; Hooker AC
    Clin Pharmacol Ther; 2010 May; 87(5):563-71. PubMed ID: 20336064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reasonable two-stage adaptive designs for single-arm phase II clinical trials.
    Kashiwabara K; Matsuyama Y
    Pharm Stat; 2018 Nov; 17(6):770-780. PubMed ID: 30168250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes.
    Seurat J; Nguyen TT; Mentré F
    Stat Methods Med Res; 2020 Mar; 29(3):934-952. PubMed ID: 31131705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive optimal design for bridging studies with an application to population pharmacokinetic studies.
    Foo LK; Duffull S
    Pharm Res; 2012 Jun; 29(6):1530-43. PubMed ID: 22350799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.
    Bouillon-Pichault M; Jullien V; Bazzoli C; Pons G; Tod M
    J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):25-40. PubMed ID: 21046208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.